Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Nov

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Opening Session Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

TIL Therapy Plus Pembrolizumab for Advanced Melanoma

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer

Current Public Knowledge Rates on Alcohol and Cancer Risks

Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer